Market Cap 19.42M
Revenue (ttm) 1.98M
Net Income (ttm) -9.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -486.36%
Debt to Equity Ratio 0.00
Volume 170,200
Avg Vol 479,758
Day's Range N/A - N/A
Shares Out 8.03M
Stochastic %K 26%
Beta 1.09
Analysts Hold
Price Target $6.00

Company Profile

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the ma...

Industry: Biotechnology
Sector: Healthcare
Phone: 801 994 7383
Fax: 801 994 7388
Address:
675 Arapeen Drive, Suite 202, Salt Lake City, United States
BaneMan666
BaneMan666 Apr. 24 at 9:55 PM
$LPCN Lipocine’s FAST ACTING SAFE oral drug for the most severe psychiatric disorder patients is best option! The FDA announced a series of measures aimed at accelerating the development of psychedelic treatments for serious mental illness. It's a significant step toward supporting psychedelic-based medicines for conditions such as treatment-resistant depression, PTSD and other substance use disorders, the agency said. The FDA also said allowing these studies to proceed does not mean the drugs are approved or proven safe and effective and that data must be closely monitored.
1 · Reply
amazingcrwns
amazingcrwns Apr. 24 at 1:15 PM
$LPCN Not much happening here for the next several weeks. I'm looking forward to the earnings report for the latest financials after ATM usage and maybe some indication of what their plans are, and then maybe a new slide deck before the annual meeting on June 3rd. I believe its still several weeks before they'll complete their full analysis of the data and submit it to the FDA. Its probably a similar timeline for them to get a response to the FastTrack and BTD applications. Then another few months for the FDA to review the complete dataset and give a response. Probably going to be a quiet summer, hopefully we get canadian approval for Tlando at some point and maybe they'll sign a new regional supplier deal or something.
1 · Reply
BioPM1989
BioPM1989 Apr. 24 at 2:50 AM
1 · Reply
bg4
bg4 Apr. 22 at 6:35 PM
$LPCN Dr. R. Dana Ono's background strongly suggests that he is a specialist in preparing companies for sale or strategically repositioning them.
4 · Reply
frontiere
frontiere Apr. 22 at 2:16 PM
$NEUP Neuphoria ex $BNOX Bionomics — Long — anyone here picked up on CEO Spyros resigning from his $LPCN Lipocine Chairmanship with a disagreement? Breadcrumbs, but I see it as a small good sign — I was a bit wary of how actively he is involved in NEUP right now. Also LPCN is an interesting cigar butt long if goes <$2.00 again ;)
1 · Reply
ACInvestorBlog
ACInvestorBlog Apr. 21 at 8:30 PM
$LPCN Lipocine Appoints R. Dana Ono As Chairman Of The Board On April 20, 2026
2 · Reply
backtesttrend
backtesttrend Apr. 21 at 2:59 PM
$LPCN is showing a bullish MACD crossover on the daily chart, signaling improving momentum. There’s also a major gap resistance around $2.63—if price can break and hold above it with volume, it could trigger a new acceleration phase. Notably, insiders recently bought roughly $434,600 worth of shares, which adds confidence to the medium-term setup. The key now is whether volume confirms the breakout.
0 · Reply
ACInvestorBlog
ACInvestorBlog Apr. 21 at 2:36 PM
$LPCN Bullish MACD crossover on daily. Mega gap over 2.63 NOTE: Insiders purchased recently a ton of shares $434,600 in total value
1 · Reply
ACInvestorBlog
ACInvestorBlog Apr. 21 at 2:17 PM
$LPCN gaining momo
0 · Reply
ACInvestorBlog
ACInvestorBlog Apr. 20 at 4:08 PM
$LPCN They buy for a reason.... Heavy insider buying = positive signal worth paying attention to. Huge gap above !
2 · Reply
Latest News on LPCN
What's Going On With Lipocine Stock On Monday?

Apr 6, 2026, 9:09 AM EDT - 23 days ago

What's Going On With Lipocine Stock On Monday?


Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®

Nov 4, 2025, 8:00 AM EST - 6 months ago

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®


Lipocine Transcript: Status Update

Jul 9, 2025, 11:00 AM EDT - 10 months ago

Lipocine Transcript: Status Update


Lipocine Receives Updated Regulatory Guidance on LPCN 1154

Feb 6, 2025, 8:00 AM EST - 1 year ago

Lipocine Receives Updated Regulatory Guidance on LPCN 1154


Lipocine Transcript: Status Update

Oct 15, 2024, 6:00 PM EDT - 1 year ago

Lipocine Transcript: Status Update


Lipocine Transcript: Study Result

Apr 10, 2024, 6:00 PM EDT - 2 years ago

Lipocine Transcript: Study Result


Lipocine to Present at 36th Annual Roth Conference

Mar 6, 2024, 8:00 AM EST - 2 years ago

Lipocine to Present at 36th Annual Roth Conference


BaneMan666
BaneMan666 Apr. 24 at 9:55 PM
$LPCN Lipocine’s FAST ACTING SAFE oral drug for the most severe psychiatric disorder patients is best option! The FDA announced a series of measures aimed at accelerating the development of psychedelic treatments for serious mental illness. It's a significant step toward supporting psychedelic-based medicines for conditions such as treatment-resistant depression, PTSD and other substance use disorders, the agency said. The FDA also said allowing these studies to proceed does not mean the drugs are approved or proven safe and effective and that data must be closely monitored.
1 · Reply
amazingcrwns
amazingcrwns Apr. 24 at 1:15 PM
$LPCN Not much happening here for the next several weeks. I'm looking forward to the earnings report for the latest financials after ATM usage and maybe some indication of what their plans are, and then maybe a new slide deck before the annual meeting on June 3rd. I believe its still several weeks before they'll complete their full analysis of the data and submit it to the FDA. Its probably a similar timeline for them to get a response to the FastTrack and BTD applications. Then another few months for the FDA to review the complete dataset and give a response. Probably going to be a quiet summer, hopefully we get canadian approval for Tlando at some point and maybe they'll sign a new regional supplier deal or something.
1 · Reply
BioPM1989
BioPM1989 Apr. 24 at 2:50 AM
1 · Reply
bg4
bg4 Apr. 22 at 6:35 PM
$LPCN Dr. R. Dana Ono's background strongly suggests that he is a specialist in preparing companies for sale or strategically repositioning them.
4 · Reply
frontiere
frontiere Apr. 22 at 2:16 PM
$NEUP Neuphoria ex $BNOX Bionomics — Long — anyone here picked up on CEO Spyros resigning from his $LPCN Lipocine Chairmanship with a disagreement? Breadcrumbs, but I see it as a small good sign — I was a bit wary of how actively he is involved in NEUP right now. Also LPCN is an interesting cigar butt long if goes <$2.00 again ;)
1 · Reply
ACInvestorBlog
ACInvestorBlog Apr. 21 at 8:30 PM
$LPCN Lipocine Appoints R. Dana Ono As Chairman Of The Board On April 20, 2026
2 · Reply
backtesttrend
backtesttrend Apr. 21 at 2:59 PM
$LPCN is showing a bullish MACD crossover on the daily chart, signaling improving momentum. There’s also a major gap resistance around $2.63—if price can break and hold above it with volume, it could trigger a new acceleration phase. Notably, insiders recently bought roughly $434,600 worth of shares, which adds confidence to the medium-term setup. The key now is whether volume confirms the breakout.
0 · Reply
ACInvestorBlog
ACInvestorBlog Apr. 21 at 2:36 PM
$LPCN Bullish MACD crossover on daily. Mega gap over 2.63 NOTE: Insiders purchased recently a ton of shares $434,600 in total value
1 · Reply
ACInvestorBlog
ACInvestorBlog Apr. 21 at 2:17 PM
$LPCN gaining momo
0 · Reply
ACInvestorBlog
ACInvestorBlog Apr. 20 at 4:08 PM
$LPCN They buy for a reason.... Heavy insider buying = positive signal worth paying attention to. Huge gap above !
2 · Reply
ACInvestorBlog
ACInvestorBlog Apr. 20 at 2:03 PM
$LPCN You sell, they buy
1 · Reply
ACInvestorBlog
ACInvestorBlog Apr. 20 at 1:50 PM
Added more shares of $LPCN thank you !!!
0 · Reply
brunoq14
brunoq14 Apr. 18 at 12:29 PM
$LPCN i have personal experience of a company whose drug received breakthrough status after a trial in which the primary objective was not met. That was Durect's Phase 2 trial of larsucosterol for alcohol-related hepatitis. Failed because European sites didn't follow protocol and admitted patients who were too old and too sick. And there was also the questionable decision to count patients who chose to have transplants as dead. Promising results in the American patients led to the FDA decision. But Durect was unable to finance the required Phase 3, and they were acquired by BHC, who is now running their own larsucosterol trial, having presumably learned a lot of things not to do from Durect.
1 · Reply
steven1x
steven1x Apr. 18 at 1:53 AM
$LPCN what’s date on pr https://filecache.investorroom.com/mr5ir_lipocine/225/download/LPCN_1154_PPD_NC_presentation_for_April_2026.pdf
1 · Reply
ACInvestorBlog
ACInvestorBlog Apr. 17 at 5:11 PM
$LPCN accumulation continues. Insiders purchased a ton of shares recently.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 17 at 12:58 PM
$LPCN RSI: 26.64, MACD: -1.5542 Vol: 2.78, MA20: 4.92, MA50: 7.15 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
silentmaxx
silentmaxx Apr. 16 at 2:43 PM
0 · Reply
BioRich
BioRich Apr. 16 at 2:00 PM
$LPCN Rare Insight... @BioRich Current Top 20: 1) GUTS 2) MIST 3) IBRX 4) UEC 5) KYTX 6) OCUL 7) DAVE 8) WVE 9) MLTX 10) CAPR 11) LPCN 12) $KTOS 13) $ADMA 14) $TGTX 15) $VKTX 16) BBAI 17) CADL 18) TLSA 19) SNDX 20) NVAX Follow/Subscribe for more insights and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
1 · Reply
SocioCobb
SocioCobb Apr. 16 at 1:37 PM
$LPCN Not bad, quick gainer.
0 · Reply
KOWALSK1
KOWALSK1 Apr. 16 at 10:03 AM
0 · Reply
amazingcrwns
amazingcrwns Apr. 15 at 7:47 PM
$LPCN saw this on the presentations page, I don't think this slide was in the updated corp presentation. I don't think anything can happen before the FDA reviews the data, but its nice to see they're already thinking about a validation study.
0 · Reply
DivvyDoo
DivvyDoo Apr. 15 at 4:00 PM
0 · Reply